🔗 Share this article

As the United States proceeds with unprecedented adjustments to its vaccine schedules, one figure appears unexpectedly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by expressing skepticism about COVID-19 vaccines throughout the pandemic and has concentrated on potential deaths following COVID-19 immunization in her short position at the Food and Drug Administration.

Proposed Overhauls to Childhood Immunization Program

Public health authorities were set to reveal major revisions to the childhood vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, sources say – a substantial departure that would put the US out of alignment with much of the global community with insufficient data for benefit. The planned update has been postponed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is listed to present at the meeting. She was recently named temporary leader of the FDA’s CDER, the fifth individual to run the office this year.

Consolidating Power at the Agency

Høeg's temporary position might represent a closer partnership between the drug and biologics centers as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it points to a renewed priority upon rolling back long-standing vaccines at the FDA.

The new acting director has repeatedly called for halting some childhood vaccine recommendations in the US so as to align more in line with the Danish model, a society with comprehensive healthcare and a population approximately the population of Wisconsin’s.

To date statements, she has kept her attention on vaccines – typically the purview of Dr. Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Questions Over Expertise

The appointee has no obvious track record in medication creation, regulation or administrative roles, which has been customary for former leaders of the CBER. She has been employed at the FDA as a top consultant to the agency head and CBER since March.

“It seems she lacks to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a large organization. She has no expertise in industry regulation.”

Former directors of the center would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, noted Janet Woodcock. “Clearly, she doesn’t have the kind of background that previous people who led the center have had.”

This division has an enormous workload at the agency, the former commissioner emphasized.

“Many people just pays attention on the new drug program, but the off-patent medication office clears thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and more, and each of these need to be managed,” she explained. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a significant administrative aspect to the position, which supervises in excess of 5,000 employees. “It’s a enormous management job, if you perform it correctly,” she added.

Response and Controversial Programs

In response to inquiries about Dr. Høeg's qualifications and whether this selection represents greater collaboration among agency officials on vaccines, a press secretary responded that the “questions stem from flawed assumptions”.

“This background matches the responsibilities of her job,” the official said, noting the time Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg takes over the agency head's new expedited review system, a contentious expedited medication authorization process that reportedly troubled her predecessors. “By what process are these drugs being picked for this expedited pathway? Who is making the calls?” Dr. Howard asked. “There is a lot of confidentiality happening at the FDA right now.”

In general, he remarked, “the agency appears to be shifting towards laxer oversight of most medications, with the exception of vaccines.”

Established History on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if troubling, past, critics have noted. She published a study using unverified volunteer-provided data to determine the incidence of heart inflammation after Covid immunization. She consulted for the Florida top health official Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Part of her “policy goals” for the current administration included altering rules for new vaccines and halting “unnecessary” immunizations, she said post-election on a online show. At the FDA, Høeg has according to sources proposed preventing teenage boys from getting Covid vaccines.

“She’s an all-around dogmatist who commences with her beliefs and works backwards to accommodate the data in a extremely misleading, untruthful fashion,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg joined other skeptics, {like|